---ITs NOT MATTER CBST at all IF TELAYANCIN gets FDA OKd
Cubist is going to make 25% to 35% per qtr in the US with competition now ( 4 now and another with possibly Theravance ) Theravance possibly( if OK’d to sell) not to sell to pregnanted woman or young kids.--------- Also CUBICIN is growing selling against taking main ---competition ---Vancomycin that genereic antibiotic and has long been the treatment of last resort. I don’t get this -----we are working about TEVA pharm. and has to court in thirty months (which CBST is covered by PATENDED) What I’m getting out is ----(CBST) will sell CUBICIN in the US -----also Phizer Inc drug company and Vancomycin generic drug are the largist companys in competition with CUBIST and (CBST) is in high growth 25% to 35% per qtr. ---------CBST does don’t have to work abount ----------Theravance getting an ok on its drug ( not safe to sell on pregnanted woman or young kids) is something CBST -------have to worry about ------ BY SWNV
cubicin doesn't see much use in pregnant patients/ kids anyway and so that doesn't really affect theravance's drug uptake...
i am most impressed by cubicin's uptake (most successful antibiotic launch in history, even better than rocepehn) this position is not easily attained and theravance's drug even if approved, will get some niche use but will not be a dominant player. (see zyvox, eraxis, merrem)